Low- versus Standard-Dose Intravenous Tissue-Type Plasminogen Activator for Acute Ischemic Stroke: An Updated Meta-Analysis

医学 改良兰金量表 置信区间 荟萃分析 优势比 内科学 脑出血 随机对照试验 子群分析 纤溶剂 临床终点 入射(几何) 组织纤溶酶原激活剂 外科 缺血性中风 缺血 蛛网膜下腔出血 物理 光学
作者
Huihui Liu,Huaguang Zheng,Yongjun Cao,Yuesong Pan,David Wang,Runhua Zhang,Shoujiang You,Xinmiao Zhang,Shuya Li,Xu Tong,Chun‐Feng Liu,Yilong Wang
出处
期刊:Journal of stroke and cerebrovascular diseases [Elsevier BV]
卷期号:27 (4): 988-997 被引量:12
标识
DOI:10.1016/j.jstrokecerebrovasdis.2017.11.005
摘要

Background We performed a meta-analysis to compare the efficacy and safety between low- and standard-dose intravenous (IV) tissue-type plasminogen activator (tPA) for acute ischemic stroke (AIS) patients within 4.5 hours of symptom onset. Methods We searched PubMed and EMBASE for relevant studies from inception to June1, 2017. Cohort or randomized controlled studies for AIS within 4.5 hours of symptom onset with comparison between low-dose and standard-dose tPA were included. The primary efficacy end point was favorable functional outcome (modified Rankin scale scores [mRS] of 0-1) at 90 days. The primary safety end point was the incidence rate of symptomatic intracerebral hemorrhage (sICH). The secondary end points were independent functional outcome (mRS scores of 0-2) and mortality. Results A total of 11 studies were pooled in this meta-analysis. The low-dose strategy appeared to be as effective as standard-dose tPA (43.4% versus 45.4%; odds ratio [OR] = 0.93, 95% confidence interval [CI]: 0.78-1.10; P = .38) in primary efficacy outcome. The secondary efficacy outcome produced similar results (57.3% versus 57.0%; OR = 0.95, 95% CI: 0.86-1.05; P = .33). There was no evidence of statistical difference for sICH (4.2% versus 4.9%; OR = 1.02 [0.66-1.55]; P = .94) and mortality (9.0% versus 10.6%; OR = 0.99 [0.74-1.31]; P = .92) at 90 days between low- and standard-dose therapy. In a subgroup analysis by ethnicity, there was no significant difference between patients of Asian and non-Asian descent for any of the end points. Conclusions This study showed that AIS patients receiving low-dose IV-tPA had comparably efficacy and safety to those receiving standard-dose IV-tPA. However, the effect is especially pronounced within the Asian population, which limits the generalizability of these results. We performed a meta-analysis to compare the efficacy and safety between low- and standard-dose intravenous (IV) tissue-type plasminogen activator (tPA) for acute ischemic stroke (AIS) patients within 4.5 hours of symptom onset. We searched PubMed and EMBASE for relevant studies from inception to June1, 2017. Cohort or randomized controlled studies for AIS within 4.5 hours of symptom onset with comparison between low-dose and standard-dose tPA were included. The primary efficacy end point was favorable functional outcome (modified Rankin scale scores [mRS] of 0-1) at 90 days. The primary safety end point was the incidence rate of symptomatic intracerebral hemorrhage (sICH). The secondary end points were independent functional outcome (mRS scores of 0-2) and mortality. A total of 11 studies were pooled in this meta-analysis. The low-dose strategy appeared to be as effective as standard-dose tPA (43.4% versus 45.4%; odds ratio [OR] = 0.93, 95% confidence interval [CI]: 0.78-1.10; P = .38) in primary efficacy outcome. The secondary efficacy outcome produced similar results (57.3% versus 57.0%; OR = 0.95, 95% CI: 0.86-1.05; P = .33). There was no evidence of statistical difference for sICH (4.2% versus 4.9%; OR = 1.02 [0.66-1.55]; P = .94) and mortality (9.0% versus 10.6%; OR = 0.99 [0.74-1.31]; P = .92) at 90 days between low- and standard-dose therapy. In a subgroup analysis by ethnicity, there was no significant difference between patients of Asian and non-Asian descent for any of the end points. This study showed that AIS patients receiving low-dose IV-tPA had comparably efficacy and safety to those receiving standard-dose IV-tPA. However, the effect is especially pronounced within the Asian population, which limits the generalizability of these results.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
HHHAN发布了新的文献求助10
1秒前
胡胡完成签到 ,获得积分10
2秒前
火星上小土豆完成签到 ,获得积分10
12秒前
杰尼龟的鱼完成签到 ,获得积分10
16秒前
安然完成签到 ,获得积分10
17秒前
张希伦完成签到 ,获得积分10
17秒前
任性翠安完成签到 ,获得积分10
21秒前
dong完成签到 ,获得积分10
23秒前
神说完成签到,获得积分0
25秒前
量子星尘发布了新的文献求助10
31秒前
Aimee完成签到 ,获得积分10
31秒前
徐彬荣完成签到,获得积分10
32秒前
研友_8yN60L完成签到,获得积分10
33秒前
搜集达人应助科研通管家采纳,获得10
33秒前
光亮的自行车完成签到 ,获得积分10
33秒前
李东东完成签到 ,获得积分10
48秒前
王多肉完成签到,获得积分10
52秒前
Iiiilr完成签到 ,获得积分10
53秒前
杨幂完成签到,获得积分10
54秒前
1分钟前
hellokitty完成签到,获得积分10
1分钟前
1分钟前
小四发布了新的文献求助10
1分钟前
1分钟前
西瓜完成签到 ,获得积分10
1分钟前
包容的忆灵完成签到 ,获得积分10
1分钟前
高兴尔冬发布了新的文献求助10
1分钟前
xiang完成签到 ,获得积分0
1分钟前
小四完成签到,获得积分10
1分钟前
FashionBoy应助slayers采纳,获得30
1分钟前
量子星尘发布了新的文献求助10
1分钟前
黑眼圈完成签到 ,获得积分10
1分钟前
jia完成签到 ,获得积分10
1分钟前
如履平川完成签到 ,获得积分10
1分钟前
科目三应助忧伤的步美采纳,获得10
1分钟前
大椒完成签到 ,获得积分10
1分钟前
1分钟前
1分钟前
wisdom完成签到,获得积分10
1分钟前
slayers发布了新的文献求助30
1分钟前
高分求助中
【提示信息,请勿应助】关于scihub 10000
Les Mantodea de Guyane: Insecta, Polyneoptera [The Mantids of French Guiana] 3000
徐淮辽南地区新元古代叠层石及生物地层 3000
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
Handbook of Industrial Diamonds.Vol2 1100
Global Eyelash Assessment scale (GEA) 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 550
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4038039
求助须知:如何正确求助?哪些是违规求助? 3575756
关于积分的说明 11373782
捐赠科研通 3305574
什么是DOI,文献DOI怎么找? 1819239
邀请新用户注册赠送积分活动 892655
科研通“疑难数据库(出版商)”最低求助积分说明 815022